CervoMed Inc.

Developing CNS therapeutics for neurodegenerative diseases like dementia with Lewy bodies.

CRVO | US

Overview

Corporate Details

ISIN(s):: US2537484048 (+1 more)
LEI:
Country:: United States of America
Address:: 20 PARK PLAZA, 2116 BOSTON
Website:: https://cervomed.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

CervoMed Inc. is a clinical-stage biotechnology company focused on developing treatments for age-related, neurodegenerative diseases. The company advances central nervous system (CNS) therapeutics by targeting synaptic dysfunction, the reversible aspect of the neurodegenerative process, in the early stages of disease. Its lead investigational product is neflamapimod, an orally administered, small molecule brain penetrant that inhibits the p38 alpha protein kinase. CervoMed is advancing neflamapimod through clinical trials, including a Phase 2 study for patients with dementia with Lewy bodies (DLB).

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
	2025-11-04 13:08	Regulatory News Service 8-K - CervoMed Inc. (0001053691) (Filer)	English	80.6 KB

Automate Your Workflow. Get a real-time feed of all CervoMed Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for CervoMed Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for CervoMed Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

	Company	Country	Ticker
	LEXICON PHARMACEUTICALS, INC. Develops gene-based drugs for chronic diseases, including treatments for heart failure.	United States of America	LXRX
$LIFECORE BIOMEDICAL, INC. \DE\ Logo$	LIFECORE BIOMEDICAL, INC. \DE\ A CDMO for parenteral drugs, producing injectable-grade sodium hyaluronate (HA).	United States of America	LFCR
	Liminatus Pharma, Inc. Clinical-stage immuno-oncology firm developing cancer therapies targeting the CD47 checkpoint.	United States of America	LIMN
	Lineage Cell Therapeutics Inc. Developing off-the-shelf cell therapies for neurological and ophthalmic conditions.	Israel	LCTX
	Lineage Cell Therapeutics, Inc. Developing off-the-shelf cell therapies for neurological and ophthalmic conditions.	United States of America	LCTX
	Lipigon Pharmaceuticals AB Develops novel drugs for lipid metabolism disorders to reduce cardiovascular disease risk.	Sweden	LPGO
	Lipocine Inc. Biopharma developing oral drugs for metabolic & endocrine disorders using delivery technology.	United States of America	LPCN
	Lipum AB Develops first-in-class antibody treatments for chronic inflammatory diseases like arthritis.	Sweden	LIPUM
	Liquidia Corp Develops inhaled therapies for rare cardiopulmonary diseases using proprietary PRINT® technology.	United States of America	LQDA
	LISATA THERAPEUTICS, INC. Oncology firm with a platform for more effective, targeted delivery of anti-cancer drugs.	United States of America	LSTA